Quantessence Capital LLC Alkermes Plc. Transaction History
Quantessence Capital LLC
- $400 Billion
- Q1 2025
A detailed history of Quantessence Capital LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Quantessence Capital LLC holds 11,300 shares of ALKS stock, worth $328,717. This represents 0.09% of its overall portfolio holdings.
Number of Shares
11,300
Previous 12,477
9.43%
Holding current value
$328,717
Previous $359 Million
3.98%
% of portfolio
0.09%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$847 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$530 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$343 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$233 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$200 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.78B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...